pharmaphorum

DECEMBER 24, 2021

The anti-amyloid drug, which also claimed a breakthrough tag from the FDA in July, is being developed for the treatment of early-stage Alzheimer’s disease. The $56,000-a-year price tag for the drug, which has now been cut in half in the US, also hasn’t helped the drugmakers make a case for Aduhelm with US payers.

FDA 111

FDA 111

pharmaphorum

APRIL 26, 2021

In 2019 Cognitant and Addenbrook’s Hospital in Cambridge, UK piloted a programme that aimed to educate patients to improve adherence to rheumatoid arthritis medicines. It comprises more than 170 companies and employs 20,000 people across 20 countries worldwide.

Hospitals 122

Hospitals 122

pharmaphorum

NOVEMBER 24, 2021

The DTx – also known as Pear-009 – is still in the proof-of-concept trial stage, but draws on the same cognitive behavioural therapy (CBT) deployed in Pear’s commercial-stage products reSET and reSET-O for people living with substance and opioid use disorders. Photo by thom masat on Unsplash.

FDA 59

FDA 59

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved.

FDA 40

FDA 40

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

FDA 52

FDA 52

pharmaphorum

JUNE 8, 2021

It also takes issue with the decision to approve the drug for all Alzheimer’s patients, rather than just the patients with mild cognitive impairment (MCI) and mild dementia included in Biogen’s studies of the drug. The post FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag appeared first on.

FDA 98

FDA Labelling 98

The Checkup by Singlecare

JANUARY 15, 2023

In reality, both categories of medication have only modest benefits for cognitive function. Aduhelm carries a hefty price tag, and it is not appropriate for any other form of dementia, such as dementia with Lewy bodies and vascular dementia. Memantine is often added to a cholinesterase inhibitor when Alzheimer’s disease worsens.

Dosage 52

Dosage FDA Insurance 52